Efficacy of Certolizumab pegol in patients with Psoriasis and Psoriatic arthritis

Trial Profile

Efficacy of Certolizumab pegol in patients with Psoriasis and Psoriatic arthritis

Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Dec 2017

At a glance

  • Drugs Certolizumab pegol (Primary)
  • Indications Psoriasis; Psoriatic arthritis
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 20 Dec 2017 New trial record
    • 01 Dec 2017 Preliminary results (n=45) assessing efficacy published in the Dermatology and Therapy.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top